🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.300
-0.080 (-2.37%)
Nov 18, 2026, 10:41 AM EST - Market open

Aclaris Therapeutics Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.82. The average 1-year stock price forecast is 197.52% higher than the current stock price, while the lowest is $3.00 (-9.09%) and the highest is $16 (+384.85%).

Price Target: $9.82 (+197.52%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$3.00$9.82$10$16
Change-9.09%+197.52%+203.03%+384.85%

Analyst Ratings

The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy99910109
Buy111111
Hold111112
Sell000000
Strong Sell000000
Total111111121212

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$13 → $12
BuyMaintains$13 → $12+263.64%Nov 17, 2026
Wedbush
Wedbush
Hold
Downgrades
$8 → $3
HoldDowngrades$8 → $3-9.09%Nov 17, 2026
Stifel Nicolaus
Stifel Nicolaus
Hold
Reiterates
$4
HoldReiterates$4+21.21%Nov 16, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$16
BuyReiterates$16+384.85%Nov 16, 2026
Unknown Analyst
Oppenheimer
No rating
Oppenheimer
Buy
Maintains
$10
BuyMaintains$10+203.03%Nov 6, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
6.50M
from 7.83M
Decreased by -16.95%
Revenue Next Year
5.12M
from 6.50M
Decreased by -21.18%
EPS This Year
-0.58
from -0.53
EPS Next Year
-0.69
from -0.58
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
6.76M29.75M31.25M18.72M7.83M6.50M
Revenue Growth
4.30%340.05%5.03%-40.09%-58.19%-16.95%
Operating Income
-65.38M-85.15M-114.51M-52.53M-74.08M-96.21M
Net Income
-90.87M-86.91M-88.48M-132.07M-64.92M-86.78M
EPS
-----0.53-0.58
Free Cash Flow
-----47.22M-81.00M
No. Analysts
-----9
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High7.8M
Avg6.5M
Low5.1M

Revenue Growth

Revenue Growth202620272028
High
-0.3%
Avg
-17.0%
Low
-34.8%

EPS Forecast

EPS202620272028
High-0.48
Avg-0.58
Low-0.72

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-